Chapter Five - The Empire of Oncology

CHAPTER FIVE

The Empire of Oncology

CANCER IS A medical condition.
But the moment you’re diagnosed, it becomes a business transaction.

A really big one.

Treatment plans, insurance codes, pharmaceutical regimens, billing cycles, procedural authorizations, drug reimbursements, hospital networks, grant funding, research subsidies, equipment leases, federal regulations, lobbying pressure, and donor campaigns.

Every diagnosis is a trigger for a machine.
And that machine is massive.

The global cancer industry is worth over $500 billion.
And it’s growing. Fast.

Because cancer rates are rising.
Because early detection is getting better.
Because treatment windows are longer.
Because survival rates have improved just enough to keep the treadmill running.

A person who dies immediately is a loss.
A person who lives with cancer for years?
That’s a revenue stream.

Let’s break it down.

When someone is diagnosed, the first step is usually a biopsy. That’s a medical procedure, billable.

Then comes imaging: CT scans, MRIs, and PET scans.
Each one costs hundreds to thousands of dollars.

Next, staging the cancer. More scans, more tests, and genetic profiling.
The deeper the analysis, the more codes you can bill.

Then treatment. Chemo. Radiation. Surgery. Maybe immunotherapy. Maybe hormone blockers.
Each with its own billing structure.
Each with its own protocol.
Each with its own price tag.

Some chemotherapy drugs cost $10,000 a month.
Some immunotherapies go much higher.
And the average cost of treating a cancer patient in the U.S. is over $150,000, sometimes double or triple that depending on the type.

Even if insurance pays, the hospital still wins.
The pharmaceutical company still wins.
The machine still feeds.

None of this means treatment is fake.
Or that doctors are evil.
Or that there’s some giant mustache-twirling villain behind the scenes.

But it does mean you have to ask:

What happens when a disease becomes profitable?

What happens when the standard of care becomes codified not by best outcomes, but by reimbursement schedules?

What happens when experimental treatments are held up for ten years because the patent situation is unclear?

What happens when oncologists operate in a reimbursement system that pays more for certain chemo brands than others?

What happens when a single drug trial costs $2 billion and takes fifteen years to complete?

What happens when “finding the cure” is less profitable than managing the disease?

Here’s the ugly truth:

You’re not just fighting cancer.
You’re fighting the cancer economy.

It’s not built to find a cure.
It’s built to treat forever.

It rewards maintenance.
It punishes simplicity.
It thrives on recurrence.

And it wraps itself in the language of hope.

Go to any cancer center and you’ll see words like:
Fight. Survivor. Journey. Warrior. Research. Hope. Cure.

What you won’t see is the billing department.
Or the pharma rep’s lunch meeting.
Or the email where a new drug was shelved because the trial results didn’t hit the “right” endpoint for marketing.

There’s hope. There’s progress. There’s real science happening every day.

But there’s also bloat. Red tape. Censorship. Profit motive.
And an unspoken rule that anyone who rocks the boat too hard doesn’t get funded next year.

If we want to cure cancer, we have to do something insane:

We have to cure the business model.

Not just the cells.
Not just the tumors.
The entire incentive structure behind how cancer is treated, tested, marketed, and priced.

Until then, the machine keeps turning.
And the war, no matter how many walks, ribbons, or breakthroughs we chant, stays unwinnable by design.